Invex Therapeutics Valuation

Is IXC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IXC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IXC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IXC's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IXC?

Key metric: As IXC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IXC. This is calculated by dividing IXC's market cap by their current revenue.
What is IXC's PS Ratio?
PS Ratio4.2x
SalesAU$1.21m
Market CapAU$5.04m

Price to Sales Ratio vs Peers

How does IXC's PS Ratio compare to its peers?

The above table shows the PS ratio for IXC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.4x
ACR Acrux
2.5x34.0%AU$12.5m
FRE Firebrick Pharma
4xn/aAU$10.9m
CGB Cann Global
9.7xn/aAU$5.4m
RNO Rhinomed
1.4xn/aAU$11.5m
IXC Invex Therapeutics
4.2xn/aAU$5.0m

Price-To-Sales vs Peers: IXC is expensive based on its Price-To-Sales Ratio (4.2x) compared to the peer average (2.6x).


Price to Sales Ratio vs Industry

How does IXC's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

17 CompaniesPrice / SalesEstimated GrowthMarket Cap
MYX Mayne Pharma Group
1.1x11.3%US$252.17m
PBP Probiotec
1.1x6.7%US$160.13m
VLS Vita Life Sciences
1.4xn/aUS$74.95m
VIT Vitura Health
0.5xn/aUS$37.81m
IXC 4.2xIndustry Avg. 4.5xNo. of Companies17PS01224364860+
17 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IXC is good value based on its Price-To-Sales Ratio (4.2x) compared to the Australian Pharmaceuticals industry average (4.5x).


Price to Sales Ratio vs Fair Ratio

What is IXC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IXC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IXC's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies